Developer docs
API playgroundTry for free, no card

Search company profiles

Genelux

Full company profile

uuid0000kzt

Namestring
Genelux
Legal namestring
Genelux Corporation
Websiteurl
genelux.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Genelux Corporation is a late clinical-stage biopharmaceutical company developing oncolytic virus immunotherapies for the treatment of cancer and inflammatory diseases. Headquartered in Westlake Village, California with R&D and a company-controlled cGMP manufacturing facility in San Diego, the company is publicly listed on NASDAQ under ticker GNLX and was founded in 2008. The company's therapeutic platform centers on a modified vaccinia virus (VACV) backbone and the proprietary CHOICE Discovery Platform, which has generated more than 500 virus constructs armed with over 110 transgenes.

The lead clinical candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified oncolytic vaccinia virus designed to act through three mechanisms: direct tumor cell killing, stimulation of tumor-specific immune response, and conversion of the tumor microenvironment from immunosuppressive ("cold") to immunoreactive ("hot"). Olvi-Vec is in an active Phase 3 registrational OnPrime trial in platinum-resistant/refractory ovarian cancer with topline data expected in the second half of 2026, and in Phase 2 for recurrent non-small cell and small cell lung cancers. Phase 2 ovarian data showed a 54% objective response rate, 11.0-month median PFS, and 15.7-month median OS. Additional programs include the V2ACT combination immunotherapy (joint venture with TVAX Biomedical) for pancreatic and other solid tumors, and the V-VET1 animal health candidate (licensed worldwide to ELIAS Animal Health).

Genelux is pre-revenue with no approved products; commercial economics will depend on regulatory approval of Olvi-Vec and future pipeline assets. Revenue model relies on future direct sales (US) plus licensing royalties through the Newsoara Biopharma partnership for Greater China and the ELIAS Animal Health license for V-VET1. Distribution currently occurs through US clinical trial sites rather than traditional commercial channels, with a small 11-50 person organization that has raised over $109M since 2023 to fund late-stage clinical development.

Short descriptiontext

Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic vaccinia virus immunotherapies for cancer, with lead candidate Olvi-Vec in Phase 3 for platinum-resistant/refractory ovarian cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWestlake Village, United States
HQ citystring
Westlake Village
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncolytic virus immunotherapy, vaccinia virus therapeutics, clinical stage biopharmaceuticals, cancer immunotherapy drugs, tumor microenvironment conversion
Industry3 codes
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncolytic Virus Immunotherapy (Clinical-Stage Biopharmaceuticals)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Development
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. No commercial products approved yet. Revenue will be generated upon regulatory approval and commercialization of Olvi-Vec and other pipeline candidates.

biospace.com
2Licensing Royalties
TypeLicensing Royalties
Description

Licensing agreements including exclusive partnership with Newsoara for Olvi-Vec development in China (Greater China Region) and exclusive worldwide licensing agreement for V-VET1 with ELIAS Animal Health. These partnerships generate licensing fees and potential royalty streams.

genelux.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1CHOICE
Description

Proprietary discovery platform serving as the foundation of Genelux's oncolytic immunotherapy product development program. CHOICE has produced more than 500 different versions of the vaccinia virus armed with over 110 transgenes.

genelux.com
+2 more records
Core offering1 text field

Genelux is a late clinical-stage biopharmaceutical company developing oncolytic virus immunotherapies for cancer and inflammatory diseases. Its lead clinical candidate Olvi-Vec (olvimulogene nanivacirepvec) is a modified vaccinia virus with a triple mode of action - direct tumor cell killing, tumor-specific immune stimulation, and conversion of immunosuppressive cold tumors to immunoreactive hot tumors - being evaluated in Phase 3 trials for platinum-resistant/refractory ovarian cancer and Phase 2 trials for recurrent lung cancers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 54% objective response rate (ORR), 11.0 months median progression-free survival (PFS), 15.7 months median overall survival (OS) in Phase 2 PRROC trial
+2 more records
Product overview1 text field

Genelux is a late clinical-stage biopharmaceutical company developing a portfolio of oncolytic virus immunotherapies centered on its lead product Olvi-Vec (olvimulogene nanivacirepvec), a modified vaccinia virus that employs a triple mode of action to treat cancer. The company's pipeline includes V2ACT Immunotherapy (a combination therapy approach developed through a joint venture) and V-VET1 (an animal health product for canine cancer). The CHOICE™ Discovery Platform serves as the proprietary engine for generating new product candidates, having produced over 500 different vaccinia virus constructs.

Product and service3 records
1Olvi-Vec (olvimulogene nanivacirepvec)
CategoryOncolytic virus immunotherapy - lead clinical candidate
Description

A modified vaccinia virus (oncolytic immunotherapy) that directly kills cancer cells, stimulates a tumor-specific immune response, and converts the tumor microenvironment from immunosuppressive (cold) to immunoreactive (hot). Being evaluated as Olvi-Vec-primed immunochemotherapy in platinum-resistant/refractory ovarian cancer and recurrent lung cancers.

2V2ACT Immunotherapy
CategoryCombination immunotherapy - clinical candidate
Description

Virus and Vaccine (Neoantigen)-Enhanced Adoptive Cell Therapy - a proprietary indication-agnostic personalized anti-cancer therapy combining neoantigen-specific effector T cell immunotherapy with oncolytic immunotherapy (Olvi-Vec). Being developed by V2ACT Therapeutics LLC joint venture for pancreatic and other solid tumor cancers.

3V-VET1
CategoryVeterinary oncology product candidate
Description

A genetically characterized, veterinary-grade replication-competent oncolytic vaccinia virus (naturally attenuated isolate) for treatment of canine cancers. Being developed by ELIAS Animal Health under an exclusive worldwide licensing agreement.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierSecondaryTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-11-21
Description

On November 21, 2021, Genelux entered into an exclusive worldwide licensing agreement for V-VET1, its clinical stage animal health product candidate, with ELIAS Animal Health. ELIAS is a biotechnology company working to advance its novel T cell-based immunotherapies for the treatment of cancer in veterinary medicine. V-VET1 is a vaccinia viral strain which selectively replicates in cancer cells causing cell death (apoptosis).

2Newsoara Biopharma Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-28
Description

On September 28, 2021, Genelux entered into an exclusive rights agreement with Newsoara Biopharma Co., Ltd for Olvi-Vec and the Genelux oncolytic virus library in the Greater China Region. Newsoara is a clinical-stage biopharmaceutical company with the mission to develop and commercialize life changing medicines for the treatment of patients with cancer, autoimmune, metabolic and other major diseases in China and around the world.

genelux.com
3V2ACT Therapeutics, LLC
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

In January 2019, V2ACT Therapeutics, LLC was formed as a joint venture between Genelux Corporation and TVAX Biomedical, Inc. to develop and test V2ACT Immunotherapy, a novel immunotherapy modality combining oncolytic virotherapy and adoptive cell therapy to safely achieve superior efficacies for the treatment of pancreatic and other solid tumor cancers.

genelux.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Amgen is the broad incumbent with the only FDA-approved oncolytic virus (T-VEC/Imlygic for melanoma), making it the most established player in the oncolytic immunotherapy space where Genelux's Olvi-Vec competes.

TypeDirect peer
Description

Replimune is a direct peer developing a portfolio of oncolytic immunotherapies (RP1, RP2, RP3) based on engineered herpes simplex virus for multiple solid tumor indications, directly competing with Genelux's Olvi-Vec program.

TypeDirect peer
Description

CG Oncology is a direct peer developing CG0070, an oncolytic virus (GM-CSF expressing adenovirus) for bladder cancer, sharing Genelux's oncolytic virus immunotherapy approach for solid tumors.

4Turnstone Biologics
TypeDirect peer
Description

Turnstone Biologics (now Turnstone Biotherapeutics) develops oncolytic virus immunotherapies combining viral therapy with immune stimulation, sharing Genelux's mechanism of converting cold tumors to hot tumors.

TypeDirect peer
Description

Candel Therapeutics develops oncolytic immunotherapies including CAN-2409 for prostate cancer, sharing Genelux's virotherapy approach to converting tumor microenvironments and generating anti-tumor immune responses.

6Oncorus
TypeEmerging player
Description

Oncorus develops intratumoral oncolytic virus immunotherapies using synthetic double-stranded RNA approaches, representing an emerging player in the oncolytic immunotherapy space adjacent to Genelux's systemic delivery approach.

TypeBroad incumbent
Description

Iovance is a leading cell therapy company with approved tumor-infiltrating lymphocyte therapies for solid tumors, sharing Genelux's focus on immuno-oncology and (via the V2ACT JV) adoptive cell therapy combinations.

8Chimeric Therapeutics
TypeEmerging player
Description

Chimeric Therapeutics develops cell therapy and oncolytic virus approaches for cancer, including former CMO Dr. Jason Litten who joined Genelux — making it thematically comparable in virotherapy and cell therapy combinations.

TypeEmerging player
Description

Artiva Biotherapeutics develops off-the-shelf NK cell therapies for cancer, sharing Genelux's interest in scalable immuno-oncology approaches; also a former employer of Genelux's new CMO.

10TVAX Biomedical
TypeDirect peer
Description

TVAX Biomedical is Genelux's joint venture partner in V2ACT Therapeutics, developing personalized cancer immunotherapies combining oncolytic virotherapy with adoptive cell therapy, making it directly comparable in the virotherapy plus cell therapy combination space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genelux

Oncolytic Virus Immunotherapy (Clinical-Stage Biopharmaceuticals)genelux.com

Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic vaccinia virus immunotherapies for cancer, with lead candidate Olvi-Vec in Phase 3 for platinum-resistant/refractory ovarian cancer.

What Genelux does

Genelux Corporation is a late clinical-stage biopharmaceutical company developing oncolytic virus immunotherapies for the treatment of cancer and inflammatory diseases. Headquartered in Westlake Village, California with R&D and a company-controlled cGMP manufacturing facility in San Diego, the company is publicly listed on NASDAQ under ticker GNLX and was founded in 2008. The company's therapeutic platform centers on a modified vaccinia virus (VACV) backbone and the proprietary CHOICE Discovery Platform, which has generated more than 500 virus constructs armed with over 110 transgenes.

The lead clinical candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified oncolytic vaccinia virus designed to act through three mechanisms: direct tumor cell killing, stimulation of tumor-specific immune response, and conversion of the tumor microenvironment from immunosuppressive ("cold") to immunoreactive ("hot"). Olvi-Vec is in an active Phase 3 registrational OnPrime trial in platinum-resistant/refractory ovarian cancer with topline data expected in the second half of 2026, and in Phase 2 for recurrent non-small cell and small cell lung cancers. Phase 2 ovarian data showed a 54% objective response rate, 11.0-month median PFS, and 15.7-month median OS. Additional programs include the V2ACT combination immunotherapy (joint venture with TVAX Biomedical) for pancreatic and other solid tumors, and the V-VET1 animal health candidate (licensed worldwide to ELIAS Animal Health).

Genelux is pre-revenue with no approved products; commercial economics will depend on regulatory approval of Olvi-Vec and future pipeline assets. Revenue model relies on future direct sales (US) plus licensing royalties through the Newsoara Biopharma partnership for Greater China and the ELIAS Animal Health license for V-VET1. Distribution currently occurs through US clinical trial sites rather than traditional commercial channels, with a small 11-50 person organization that has raised over $109M since 2023 to fund late-stage clinical development.

Genelux firmographics

Firmographics
Name
Genelux
Legal name
Genelux Corporation
Website
https://genelux.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic vaccinia virus immunotherapies for cancer, with lead candidate Olvi-Vec in Phase 3 for platinum-resistant/refractory ovarian cancer.
Ownership category
akta.pro rank

Genelux industry classification

Industry
Product category
Oncolytic Virus Immunotherapy (Clinical-Stage Biopharmaceuticals)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • Oncolytic virus immunotherapy
  • Vaccinia virus therapeutics
  • Clinical stage biopharmaceuticals
  • Cancer immunotherapy drugs
  • Tumor microenvironment conversion

Where Genelux is headquartered

Location

Headquarters

HQ city
Westlake Village
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Genelux business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Pharmaceutical Development: Pre-revenue clinical-stage biopharmaceutical company. No commercial products approved yet. Revenue will be generated upon regulatory approval and commercialization of Olvi-Vec and other pipeline candidates.
  2. Licensing Royalties: Licensing agreements including exclusive partnership with Newsoara for Olvi-Vec development in China (Greater China Region) and exclusive worldwide licensing agreement for V-VET1 with ELIAS Animal Health. These partnerships generate licensing fees and potential royalty streams.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Genelux product offering

Product offering

Core offering

Genelux is a late clinical-stage biopharmaceutical company developing oncolytic virus immunotherapies for cancer and inflammatory diseases. Its lead clinical candidate Olvi-Vec (olvimulogene nanivacirepvec) is a modified vaccinia virus with a triple mode of action - direct tumor cell killing, tumor-specific immune stimulation, and conversion of immunosuppressive cold tumors to immunoreactive hot tumors - being evaluated in Phase 3 trials for platinum-resistant/refractory ovarian cancer and Phase 2 trials for recurrent lung cancers.

Product overview

Genelux is a late clinical-stage biopharmaceutical company developing a portfolio of oncolytic virus immunotherapies centered on its lead product Olvi-Vec (olvimulogene nanivacirepvec), a modified vaccinia virus that employs a triple mode of action to treat cancer. The company's pipeline includes V2ACT Immunotherapy (a combination therapy approach developed through a joint venture) and V-VET1 (an animal health product for canine cancer). The CHOICE™ Discovery Platform serves as the proprietary engine for generating new product candidates, having produced over 500 different vaccinia virus constructs.

Differentiator

Problem solved

Functional benefit

Brands

  • CHOICE: Proprietary discovery platform serving as the foundation of Genelux's oncolytic immunotherapy product development program. CHOICE has produced more than 500 different versions of the vaccinia virus armed with over 110 transgenes.
  • V2ACT
  • Olvi-Vec

Products and services

  • Olvi-Vec (olvimulogene nanivacirepvec) A modified vaccinia virus (oncolytic immunotherapy) that directly kills cancer cells, stimulates a tumor-specific immune response, and converts the tumor microenvironment from immunosuppressive (cold) to immunoreactive (hot). Being evaluated as Olvi-Vec-primed immunochemotherapy in platinum-resistant/refractory ovarian cancer and recurrent lung cancers.
  • V2ACT Immunotherapy Virus and Vaccine (Neoantigen)-Enhanced Adoptive Cell Therapy - a proprietary indication-agnostic personalized anti-cancer therapy combining neoantigen-specific effector T cell immunotherapy with oncolytic immunotherapy (Olvi-Vec). Being developed by V2ACT Therapeutics LLC joint venture for pancreatic and other solid tumor cancers.
  • V-VET1 A genetically characterized, veterinary-grade replication-competent oncolytic vaccinia virus (naturally attenuated isolate) for treatment of canine cancers. Being developed by ELIAS Animal Health under an exclusive worldwide licensing agreement.

Quantifiable outcome

  • 54% objective response rate (ORR), 11.0 months median progression-free survival (PFS), 15.7 months median overall survival (OS) in Phase 2 PRROC trial
  • +2 more outcomes

Companies that use Genelux

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Genelux technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Genelux partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered secondary and core.

  • ELIAS Animal HealthsecondaryOEM/ Whitelabel/ Licensing Partner · 21 November 2021On November 21, 2021, Genelux entered into an exclusive worldwide licensing agreement for V-VET1, its clinical stage animal health product candidate, with ELIAS Animal Health. ELIAS is a biotechnology company working to advance its novel T cell-based immunotherapies for the treatment of cancer in veterinary medicine. V-VET1 is a vaccinia viral strain which selectively replicates in cancer cells causing cell death (apoptosis).
  • Newsoara Biopharma Co., Ltd.coreStrategic or Co-development Partner · 28 September 2021On September 28, 2021, Genelux entered into an exclusive rights agreement with Newsoara Biopharma Co., Ltd for Olvi-Vec and the Genelux oncolytic virus library in the Greater China Region. Newsoara is a clinical-stage biopharmaceutical company with the mission to develop and commercialize life changing medicines for the treatment of patients with cancer, autoimmune, metabolic and other major diseases in China and around the world.
  • V2ACT Therapeutics, LLCcoreStrategic or Co-development Partner · 1 January 2019In January 2019, V2ACT Therapeutics, LLC was formed as a joint venture between Genelux Corporation and TVAX Biomedical, Inc. to develop and test V2ACT Immunotherapy, a novel immunotherapy modality combining oncolytic virotherapy and adoptive cell therapy to safely achieve superior efficacies for the treatment of pancreatic and other solid tumor cancers.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Genelux competitors and assessment

Company assessment

Broad incumbents

  • Amgen: Amgen is the broad incumbent with the only FDA-approved oncolytic virus (T-VEC/Imlygic for melanoma), making it the most established player in the oncolytic immunotherapy space where Genelux's Olvi-Vec competes.
  • Iovance Biotherapeutics: Iovance is a leading cell therapy company with approved tumor-infiltrating lymphocyte therapies for solid tumors, sharing Genelux's focus on immuno-oncology and (via the V2ACT JV) adoptive cell therapy combinations.

Direct peers

  • Replimune: Replimune is a direct peer developing a portfolio of oncolytic immunotherapies (RP1, RP2, RP3) based on engineered herpes simplex virus for multiple solid tumor indications, directly competing with Genelux's Olvi-Vec program.
  • CG Oncology: CG Oncology is a direct peer developing CG0070, an oncolytic virus (GM-CSF expressing adenovirus) for bladder cancer, sharing Genelux's oncolytic virus immunotherapy approach for solid tumors.
  • Turnstone Biologics: Turnstone Biologics (now Turnstone Biotherapeutics) develops oncolytic virus immunotherapies combining viral therapy with immune stimulation, sharing Genelux's mechanism of converting cold tumors to hot tumors.
  • Candel Therapeutics: Candel Therapeutics develops oncolytic immunotherapies including CAN-2409 for prostate cancer, sharing Genelux's virotherapy approach to converting tumor microenvironments and generating anti-tumor immune responses.
  • TVAX Biomedical: TVAX Biomedical is Genelux's joint venture partner in V2ACT Therapeutics, developing personalized cancer immunotherapies combining oncolytic virotherapy with adoptive cell therapy, making it directly comparable in the virotherapy plus cell therapy combination space.

Emerging players

  • Oncorus: Oncorus develops intratumoral oncolytic virus immunotherapies using synthetic double-stranded RNA approaches, representing an emerging player in the oncolytic immunotherapy space adjacent to Genelux's systemic delivery approach.
  • Chimeric Therapeutics: Chimeric Therapeutics develops cell therapy and oncolytic virus approaches for cancer, including former CMO Dr. Jason Litten who joined Genelux — making it thematically comparable in virotherapy and cell therapy combinations.
  • Artiva Biotherapeutics: Artiva Biotherapeutics develops off-the-shelf NK cell therapies for cancer, sharing Genelux's interest in scalable immuno-oncology approaches; also a former employer of Genelux's new CMO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Genelux social profiles

Digital presence

Genelux financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genelux leadership team

Management profile

Number of profiles

Profiles12 records

Genelux subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Genelux funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genelux M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genelux

What does Genelux do?

Genelux is a late clinical-stage biopharmaceutical company developing oncolytic virus immunotherapies for cancer and inflammatory diseases. Its lead clinical candidate Olvi-Vec (olvimulogene nanivacirepvec) is a modified vaccinia virus with a triple mode of action - direct tumor cell killing, tumor-specific immune stimulation, and conversion of immunosuppressive cold tumors to immunoreactive hot tumors - being evaluated in Phase 3 trials for platinum-resistant/refractory ovarian cancer and Phase 2 trials for recurrent lung cancers.

Is Genelux a public or private company?

Genelux is a public company. It is classified as public and is currently operating.

When was Genelux founded?

Genelux was founded in 2008. It employs 11 to 50 people.

Where is Genelux based?

Genelux is headquartered in Westlake Village, United States, in the North America region.

How does Genelux make money?

Two revenue lines are on record. Pharmaceutical Development is the primary driver. The others are licensing Royalties.

Who are Genelux's main competitors?

Broad incumbents on record are Amgen and Iovance Biotherapeutics. Direct peers are Replimune, CG Oncology, Turnstone Biologics, Candel Therapeutics and TVAX Biomedical. Emerging players are Oncorus, Chimeric Therapeutics and Artiva Biotherapeutics.

Does Genelux have an API?

No public API is recorded for Genelux.

What industry is Genelux in?

Genelux's product category is Oncolytic Virus Immunotherapy (Clinical-Stage Biopharmaceuticals). Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Dealroom.coGenelux raises $5.1M to fund cancer trial into Q1 2027 | Dealroom NewsGenelux raised $5.1 million net by selling 2.55 million shares through its at-the-market program in October and November. The proceeds lifted cash to $15.5 million, funding operations into Q1 2027. The company's third-quarter net loss widened to $10.3 million, and it cited substantial doubt about its ability to continue as a going concern.YahooGenelux Corporation Reports Third Quarter Financial Results and Provides Business UpdatesGenelux reported Q3 2026 net loss of $10.3 million and $15.5 million in pro forma cash, expecting operations to fund into Q1 2027. The company highlighted Phase 3 OnPrime topline data expected in H2 2026 and a lung cancer case report showing durable response in platinum-relapsed SCLC.GlobeNewswireGenelux Corporation Reports Third Quarter Financial Results and Provides Business UpdatesGenelux reported Q3 2026 net loss of $10.3 million and cash of $10.4 million, with $5.1 million raised under its ATM agreement. The company expects to fund operations into Q1 2027. Phase 3 OnPrime topline data is expected in H2 2026, and lung cancer dose-escalation updates are planned by year-end.Markets DailyGenelux (GNLX) Set to Post Quarterly Earnings on WednesdayGenelux is set to report Q3 2026 earnings on Wednesday, with analysts expecting a loss of $0.20 per share. The company previously missed estimates with a $0.21 loss, and insiders sold 47,822 shares in the last 90 days. The stock opened at $2.05, with a consensus target of $20.00.MarketBeatGenelux (GNLX) Projected to Release Earnings on WednesdayGenelux is projected to release Q3 2026 earnings before market open on November 4th, with analysts expecting a loss of $0.20 per share. The company's consensus price target is $20.00, and insiders sold shares in August.American Banking and Market NewsGenelux (NASDAQ:GNLX) Stock Rating Upgraded by Wall Street ZenWall Street Zen upgraded Genelux from strong sell to sell, while other analysts have mixed ratings. The stock opened at $2.45, with a consensus price target of $18.00. The company reported a loss of $0.21 per share for the quarter, missing estimates.American Banking and Market NewsGenelux Corporation (NASDAQ:GNLX) Stock Has Average Price Target of $18.00 According to AnalystsAnalysts rate Genelux Corporation with an average price target of $18.00, with a Moderate Buy consensus. Insiders Yong Yu and CEO Thomas Zindrick sold shares on August 31st, and institutional investors hold 37.33% of the stock. The company reported a loss of $0.21 per share for the quarter, missing estimates.MarketBeatGenelux Corporation (NASDAQ:GNLX) Stock Has Consensus Price Target of $18.00 According to AnalystsAnalysts assign Genelux a consensus price target of $18.00 with a Moderate Buy rating. Insiders sold 47,822 shares in 90 days, and institutional investors hold 37.33% of the stock. The company reported a loss of $0.21 per share, missing estimates.MarketBeatGenelux (NASDAQ:GNLX) Stock Rating Lowered by Wall Street ZenWall Street Zen downgraded Genelux from sell to strong sell, while Lucid Cap Mkts upgraded it to strong-buy. The stock opened at $2.56, and insiders sold 47,822 shares over three months. Analysts have a consensus Moderate Buy rating with a $18 price target.Markets DailyHead-To-Head Analysis: Foghorn Therapeutics (NASDAQ:FHTX) vs. Genelux (NASDAQ:GNLX)A head-to-head comparison of Foghorn Therapeutics and Genelux evaluates profitability, valuation, and analyst ratings. Genelux has a higher consensus rating and a larger upside potential, while Foghorn Therapeutics beats on 8 of 15 factors.